Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
LM11A-31 HCl,a non-peptide p75NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist,in preventing diabetes-induced BRB breakdown. Treating macular oedema, a leading cause of blindness in people with diabetes, may be made easier, safer, and less invasive by targeting p75NTR signalling with the oral bioavailable receptor modulator LM11A-31. A derivative of amino acid that has a high blood-brain barrier permeability and inhibits p75-mediated cell death is LM11A-31 dihydrochloride. M11A-31 dihydrochloride reverses cholinergic neurite dystrophy in mouse models of Alzheimer's disease that progress from a mid- to a late stage.
Targets |
proNGF
|
---|---|
ln Vivo |
LM11A-31 (oral gavage; 50 mg kg/day for 4 weeks) significantly reduces the build-up of proNGF and maintains the integrity of BRB[1].
LM11A-31 (orally; 50 or 75 mg/kg) given for three months beginning at 6–8 months of age prevents and/or reverses atrophy of basal forebrain cholinergic neurites and cortical dystrophic neurites in mid-stage male APPL/S mice[2]. |
Animal Protocol |
Male C57BL/6 J mice
50 mg kg/day Oral gavage; for 4 weeks |
References |
|
Molecular Formula |
C12H25N3O2
|
---|---|
Molecular Weight |
316.267
|
Exact Mass |
315.15
|
Elemental Analysis |
C, 45.57; H, 8.61; Cl, 22.42; N, 13.29; O, 10.12
|
CAS # |
1243259-19-9
|
Related CAS # |
(Rac)-LM11A-31 dihydrochloride; 1214672-15-7
|
Appearance |
Solid powder
|
SMILES |
CC[C@H](C)[C@@H](C(=O)NCCN1CCOCC1)N.Cl.Cl
|
InChi Key |
LLIHJRRZJDEKLB-ULEGLUPFSA-N
|
InChi Code |
InChI=1S/C12H25N3O2.2ClH/c1-3-10(2)11(13)12(16)14-4-5-15-6-8-17-9-7-15;;/h10-11H,3-9,13H2,1-2H3,(H,14,16);2*1H/t10-,11-;;/m0../s1
|
Chemical Name |
(2S,3S)-2-amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide;dihydrochloride
|
Synonyms |
LM11A-31 HCl; LM11A-31 hydrochloride; LM11A-31; LM11A 31; LM11A31; LM 11A-31; LM 11A31; LM-11A-31;
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O: ~100 mg/mL (~316.2 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (316.19 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.1619 mL | 15.8093 mL | 31.6186 mL | |
5 mM | 0.6324 mL | 3.1619 mL | 6.3237 mL | |
10 mM | 0.3162 mL | 1.5809 mL | 3.1619 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Impact of treatment with LM11A-31 on the proNGF/NGF ratio in the retina of mouse models of diabetes. Diabetologia . 2019 Aug;62(8):1488-1500. td> |
Impact of treatment with LM11A-31 on retinal and circulatory inflammation in mice. Diabetologia . 2019 Aug;62(8):1488-1500. td> |
Impact of treatment with LM11A-31 on mouse retinal VEGF expression and vascular permeability. Diabetologia . 2019 Aug;62(8):1488-1500. td> |
LM11A-31 prevents atrophy of cholinergic neurites in basal forebrain of late-stage APPL/S mice. PLoS One . 2014 Aug 25;9(8):e102136. td> |
LM11A-31 reverses dystrophy of cholinergic neurites that occurs with aging in APPL/S mice. PLoS One . 2014 Aug 25;9(8):e102136. td> |